ERBB2 and breast carcinoma: DCZ3112 inhibited proliferation of HER2-positive breast cancer cells and overcame trastuzumab resistance, while reducing AKT and ERK phosphorylation (Fig. 6).57 DCZ3112 selectively suppressed the growth of HER2-positive breast-cancer cells, yielding IC50 values of 7.9 μM in SK-BR-3 and 4.6 μM in BT-474.